General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience

Öz:

Objectives: Carcinoid syndrome is one of the functional neuroendocrin tumor symptom. It is a very rare disease and alittle known about this syndrome. We aimed a study that evaluating general characteristics and prognostic factors onsurvival in NET patients diagnosed with carcinoid syndrome.Methods: All patients diagnosed with neuroendocrine tumor were retrospectively reviewed in our institution. Thepatients diagnosed carsinoid syndrome were included in this study. General characteristics were recorded. Prognosticfactors on survival were analysed with Cox regression. Kaplan Meier method was used for overall survival.Results: Among 450 patients diagnosed neuroendocrine tumor in our hospital, 29 of them (6.4%) were presented withcarcinoid syndrome. The univariate analysis revealed that age, high tumor grade and ki67 score were correlated withpoor overall survival and the multivariate analyses revealed that older age were correlated with poor overall survival.The median OS were 61 months in all grades and 64 months for grade 1 tumors, 45 (13-76) months for grade 2 tumors,5 months for grade 3 tumors and there were statistically significant difference (p=0.007).Conclusion: Age, grade, ki67 score are important prognostic factor. Age is an independent prognostic factor that affecting survival in carcinoid syndrome patients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik

1. Charles W. Kimbrough, Eliza W. Beal, Mary E. Dillhoff, Carl R. Schmidt, Timothy M. Pawlik, Alexandra G. Lopez-Aguiar et al., Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection, Surgery, 2018;10:25.
2. Ozaslan E, Bayram F, Karaca H, Gursoy S, Ozturk F, Sozuer E et al., Best Prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single- center study. Turk J Gastroenterol 2016;27:509–14.
3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72.
4. Beilei C, Broder MS, Eunice C,Yan T, Metz TC, Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors, World J Gastroenterol 2017;23:7283–91.
5. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525–34.
6. Grozinsky-Glasberg S, GrossmanAB&GrossDJ, Carcinoid heart disease: from pathophysiology to treatment – ‘something in the way it moves’. Neuroendocrinology 2015;101:263–73
7. Wouter T Zandee, Kimberly Kamp, Roxanne C van Adrichem, Richard A Feelders and Wouter W de Herder, Effect of hormone secretory syndromes on neuroendocrine tumor prognosis, Endocrine Realated Cancer 2017:24;R261–R274.
8. Bosman FT (2010). World Health Organization; International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer.
9. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224–33.
10. Kirshbom, P.M., Kherani, A.R., Onaitis, M.W. et al, Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998;124:1063–1070.
11. Jerome M Feldman, R. Scott Jones, Carcinoid syndrom from gastrointestinal carcinoids without liver metastasis, Ann Surg 1982;196:1.
12. Haq AU, Yook CR, Hiremath V, Kasimis BS. Carcinoid syndrome in the absence of liver metastasis: A case report and review of literature. Med Pediatr Oncol 1992;20:221–3.
13. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–90.
14. Tian T, Gao J, Li N, Li Y, Lu M, Li Z et al Circulating Chromogranin A as a marker for monitoring clinical response in advanced gastroenteropancreatic neuroendocrine tumors, PLOS ONE: 2016;11:e0154679.
15. Rudolf Arnold, Alexandra Wilke, Anja Rınke, Christina Mayer, Peter Herbert Kann, Klaus–Jochen Klose et al. Plasma Chromogranin A as Marker for Survival in Patients With Metastatic Endocrine Gastroenteropancreatic Tumors, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:820–7.
16. Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role: Ann Oncol 2003;14:1135–41.
17. E. Baudin, A. Gigliotti, M. Ducreux, J. Ropers, E. Comoy, JC Sabourin et al, Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours, Britsh Journal of Cancer 1998;78:1102–7.
18. Anna Zaira Manfe, Lorenzo Norberto, Marco Marchesını And Franco Lumachi, Usefulness of Chromogranin A, Neuron-specific Enolase and 5-Hydroxyindolacetic Acid Measurements in Patients with Malignant Carcinoids, in vivo 2011;25:1027–30.
19. R. C. S. van Adrichem1, K. Kamp1, T. Vandamme, M. Peeters, R. A. Feelders &W.W. de Herder, Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors, Annals of Oncology 2016;27:4.
20. Mota JM, Sousa LG, and Riechelmann RP (2016) Complications from carcinoid syndrome: review of the current evidence E cance rmedical science: 10;662.
21. Bhattacharyya S, Toumpanakis C, and Caplin ME, et al (2008) Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century Am J Cardiol 101;378–81.

APA	dogan e, İnanç M, DURSUN H, Abdulrezzak U, Öztürk F, Sözüer E, Can Sezgin G, Gürsoy S, Ozkan M, yurci a, bayram f (2020). General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. , 347 - 352. 10.14744/ejmi.2020.39512
Chicago	dogan ender,İnanç Mevlüde,DURSUN HÜSEYİN,Abdulrezzak Ummuhan,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,Ozkan Metin,yurci alper,bayram fahri General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. (2020): 347 - 352. 10.14744/ejmi.2020.39512
MLA	dogan ender,İnanç Mevlüde,DURSUN HÜSEYİN,Abdulrezzak Ummuhan,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,Ozkan Metin,yurci alper,bayram fahri General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. , 2020, ss.347 - 352. 10.14744/ejmi.2020.39512
AMA	dogan e,İnanç M,DURSUN H,Abdulrezzak U,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,Ozkan M,yurci a,bayram f General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. . 2020; 347 - 352. 10.14744/ejmi.2020.39512
Vancouver	dogan e,İnanç M,DURSUN H,Abdulrezzak U,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,Ozkan M,yurci a,bayram f General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. . 2020; 347 - 352. 10.14744/ejmi.2020.39512
IEEE	dogan e,İnanç M,DURSUN H,Abdulrezzak U,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,Ozkan M,yurci a,bayram f "General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience." , ss.347 - 352, 2020. 10.14744/ejmi.2020.39512
ISNAD	dogan, ender vd. "General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience". (2020), 347-352. https://doi.org/10.14744/ejmi.2020.39512

APA	dogan e, İnanç M, DURSUN H, Abdulrezzak U, Öztürk F, Sözüer E, Can Sezgin G, Gürsoy S, Ozkan M, yurci a, bayram f (2020). General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. Eurasian Journal of Medical Investigation, 4(3), 347 - 352. 10.14744/ejmi.2020.39512
Chicago	dogan ender,İnanç Mevlüde,DURSUN HÜSEYİN,Abdulrezzak Ummuhan,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,Ozkan Metin,yurci alper,bayram fahri General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. Eurasian Journal of Medical Investigation 4, no.3 (2020): 347 - 352. 10.14744/ejmi.2020.39512
MLA	dogan ender,İnanç Mevlüde,DURSUN HÜSEYİN,Abdulrezzak Ummuhan,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,Ozkan Metin,yurci alper,bayram fahri General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. Eurasian Journal of Medical Investigation, vol.4, no.3, 2020, ss.347 - 352. 10.14744/ejmi.2020.39512
AMA	dogan e,İnanç M,DURSUN H,Abdulrezzak U,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,Ozkan M,yurci a,bayram f General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. Eurasian Journal of Medical Investigation. 2020; 4(3): 347 - 352. 10.14744/ejmi.2020.39512
Vancouver	dogan e,İnanç M,DURSUN H,Abdulrezzak U,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,Ozkan M,yurci a,bayram f General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. Eurasian Journal of Medical Investigation. 2020; 4(3): 347 - 352. 10.14744/ejmi.2020.39512
IEEE	dogan e,İnanç M,DURSUN H,Abdulrezzak U,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,Ozkan M,yurci a,bayram f "General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience." Eurasian Journal of Medical Investigation, 4, ss.347 - 352, 2020. 10.14744/ejmi.2020.39512
ISNAD	dogan, ender vd. "General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience". Eurasian Journal of Medical Investigation 4/3 (2020), 347-352. https://doi.org/10.14744/ejmi.2020.39512